Targeting cyclooxygenase-2 in human neoplasia: rationale and promise.
about
COX-2 inhibition is neither necessary nor sufficient for celecoxib to suppress tumor cell proliferation and focus formation in vitroCyanidin-3-glucoside, a natural product derived from blackberry, exhibits chemopreventive and chemotherapeutic activityEndothelin receptors as novel targets in tumor therapyG Protein-Coupled Receptors in CancerEmerging phytochemicals for prevention of melanoma invasionThe Anti-Cancer Effect of Polyphenols against Breast Cancer and Cancer Stem Cells: Molecular MechanismsGenetic polymorphisms in the cyclooxygenase-2 gene, use of nonsteroidal anti-inflammatory drugs, and breast cancer riskNonsteroidal antiinflammatory drug use and risk of bladder cancer in the health professionals follow-up studySecondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trialKaposi's sarcoma associated herpes virus (KSHV) induced COX-2: a key factor in latency, inflammation, angiogenesis, cell survival and invasionSinomenine sensitizes multidrug-resistant colon cancer cells (Caco-2) to doxorubicin by downregulation of MDR-1 expressionEarly Carcinogenesis Involves the Establishment of Immune Privilege via Intrinsic and Extrinsic Regulation of Indoleamine 2,3-dioxygenase-1: Translational Implications in Cancer Immunotherapy.Tumors as organs: complex tissues that interface with the entire organismPhase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers.Restoration of E-cadherin expression by selective Cox-2 inhibition and the clinical relevance of the epithelial-to-mesenchymal transition in head and neck squamous cell carcinomaCOX-2 and prostaglandin EP3/EP4 signaling regulate the tumor stromal proangiogenic microenvironment via CXCL12-CXCR4 chemokine systems.Effects of cigarette smoke on the human oral mucosal transcriptomePGE2 receptor EP2 mediates the antagonistic effect of COX-2 on TGF-beta signaling during mammary tumorigenesis.Wnt/β-catenin signaling enhances cyclooxygenase-2 (COX2) transcriptional activity in gastric cancer cells.C-reactive protein as an adverse prognostic marker for men with castration-resistant prostate cancer (CRPC): confirmatory results.Grape seed proanthocyanidins inhibit melanoma cell invasiveness by reduction of PGE2 synthesis and reversal of epithelial-to-mesenchymal transition.Significance of cyclooxygenase-2 in prognosis, targeted therapy and chemoprevention of NSCLC.Inactivating mutation in the prostaglandin transporter gene, SLCO2A1, associated with familial digital clubbing, colon neoplasia, and NSAID resistance.Anti-endothelin drugs in solid tumors.Role of cyclooxygenase-2 in tumor progression and survival of head and neck squamous cell carcinomaGreen tea catechins reduce invasive potential of human melanoma cells by targeting COX-2, PGE2 receptors and epithelial-to-mesenchymal transition.Effect of medical and surgical treatment of Barrett's metaplasiaInvolvement of eicosanoids in the pathogenesis of pancreatic cancer: the roles of cyclooxygenase-2 and 5-lipoxygenase.Coordinated increased expression of Cyclooxygenase2 and nuclear factor κB is a steady feature of urinary bladder carcinogenesisAdenosine and prostaglandin E2 cooperate in the suppression of immune responses mediated by adaptive regulatory T cellsVaccines and immunotherapeutics for the treatment of malignant diseaseIs there a common upstream link for autophagic and apoptotic cell death in human high-grade gliomas?Seminal plasma induces the expression of IL-1α in normal and neoplastic cervical cells via EP2/EGFR/PI3K/AKT pathway.Down-regulation of glucose-regulated protein (GRP) 78 potentiates cytotoxic effect of celecoxib in human urothelial carcinoma cells.Apricoxib, a novel inhibitor of COX-2, markedly improves standard therapy response in molecularly defined models of pancreatic cancer.Animal models and therapeutic molecular targets of cancer: utility and limitations.Cyclooxygenase inhibitors modulate the p53/HDM2 pathway and enhance chemotherapy-induced apoptosis in neuroblastoma.Combined effects of cyclooxygenase-1 and cyclooxygenase-2 selective inhibitors on ovarian carcinoma in vivo.The significance of Notch1 compared with Notch3 in high metastasis and poor overall survival in hepatocellular carcinoma.Inhibitors of indoleamine 2,3-dioxygenase: a review of novel patented lead compounds.
P2860
Q21245723-1D9C472D-5B5B-4ED0-9EAF-3A423F17A059Q23917302-E5921537-E55A-4621-B13C-7C7FA49A20DCQ24797288-790963A6-E7EF-42BA-A167-85A6B3CCD621Q26741203-842D43CE-ADB6-4BC2-A68F-536432003A46Q27023283-3F7575ED-A569-4DEC-8802-DA875ABDACFEQ28066752-3AC229F9-29AC-4A8B-BAD0-B6C39A979AC1Q28213217-D0312467-C650-4025-8AE1-451A1F9DB6E3Q28218868-866326D6-BADD-41AF-8974-4159FD447E3DQ28222007-15D6404B-29B7-4286-928A-A8F192652714Q28472867-914297F0-201D-40B2-A872-53994E250B93Q28539407-A4B3D36A-79C5-4833-9A7E-32E516691046Q30410002-E4CA7BA6-CD1C-4AC7-B401-F2F64292FECBQ30495528-569259BC-C830-4D22-9D4E-94D3E17A1F6AQ33561179-11273BCD-6176-4FC7-B2E5-F85C8135A443Q33646333-D2D75B6D-261F-4888-A4DF-FA647B1D3E0CQ33703810-E938711A-D1A7-4459-8072-B82BECF0F0E0Q33707973-BEE62CB6-DDA7-4A3F-85F4-B93A4BFB3052Q33752909-8B80D2CB-9BC2-44FB-95C9-5D390E9BC8BAQ33873644-967BA8F2-DD8E-4929-B7ED-0CBA04EA7ECBQ33949736-3FD11D3B-65F3-4757-AB43-5C9D707E29FAQ33955027-1FD15B05-A3D8-4E78-956A-3CE8A9155BE5Q34003141-28F07572-7BB7-42E0-B31B-7E69E13AF424Q34017114-CB779A50-83ED-4738-8AA2-C3313E0C8841Q34021011-BE38AAB2-97CE-4DF6-B827-F6B596C46F82Q34021476-97335FEE-12C9-42DD-AA97-BA5C03C1E3A5Q34055550-B39F7DE2-6F1F-4C30-927A-13A4B30FE99AQ34063700-E71DD491-B085-4E22-9A05-6298C2A9E40CQ34067846-45BEA477-8C79-4200-AD1B-D02B61F3667FQ34106055-0F224A8B-D1D7-43AE-936D-8747E06C5060Q34107172-4D709D18-C8EF-42A0-BBAE-C179318D878FQ34170074-4994753F-2F3F-4259-8FC3-37623151DC10Q34197351-433767E3-2096-4DB8-89CB-DD3DAF645A17Q34199061-A474180F-548C-4BE2-B8FD-1F79E2880026Q34206376-B65F53DC-4780-46CF-8A10-463AA3088528Q34290118-113057B9-7BB6-4029-A559-D3E568493DD9Q34386828-C153B52E-D9BC-4F6A-9CF3-21787AD8C5E9Q34567032-7338467C-78D2-442B-9177-644A0A7AB742Q34578154-415F6550-EE9E-44A5-AFB2-CD65A3CC7FF7Q34612059-1765B250-3EE5-4846-9118-B13B611EE661Q34616168-C3796433-7F98-4E42-8CDA-F43A41B9E7C1
P2860
Targeting cyclooxygenase-2 in human neoplasia: rationale and promise.
description
2003 nî lūn-bûn
@nan
2003 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Targeting cyclooxygenase-2 in human neoplasia: rationale and promise.
@ast
Targeting cyclooxygenase-2 in human neoplasia: rationale and promise.
@en
Targeting cyclooxygenase-2 in human neoplasia: rationale and promise.
@nl
type
label
Targeting cyclooxygenase-2 in human neoplasia: rationale and promise.
@ast
Targeting cyclooxygenase-2 in human neoplasia: rationale and promise.
@en
Targeting cyclooxygenase-2 in human neoplasia: rationale and promise.
@nl
prefLabel
Targeting cyclooxygenase-2 in human neoplasia: rationale and promise.
@ast
Targeting cyclooxygenase-2 in human neoplasia: rationale and promise.
@en
Targeting cyclooxygenase-2 in human neoplasia: rationale and promise.
@nl
P1433
P1476
Targeting cyclooxygenase-2 in human neoplasia: rationale and promise.
@en
P2093
Andrew J Dannenberg
Kotha Subbaramaiah
P304
P356
10.1016/S1535-6108(03)00310-6
P577
2003-12-01T00:00:00Z